Ibrutinib: Additional Phase Ib/II data

Data from 31 evaluable treatment-naïve patients aged 65 and older in the open-label, U.S. Phase Ib/II PCYC-1102-CA trial showed that once-daily 420 mg oral PCI-32765 led

Read the full 267 word article

User Sign In